Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.5850
-0.0486 (-7.67%)
At close: Nov 5, 2026, 4:00 PM EST
0.6167
+0.0317 (5.42%)
After-hours: Nov 5, 2026, 7:52 PM EST
Invivyd Revenue
Invivyd had revenue of $14.29M in the quarter ending June 30, 2026, with 21.20% growth. This brings the company's total for the last twelve months to $58.37M, up 26.30% year-over-year. In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth. That makes Invivyd the 26,807th largest company in the world by revenue and 3,660th in the United States.
Revenue (ttm)
$58.37M
Revenue Growth
+26.30%
P/S Ratio
2.95
Revenue / Employee
$478,402
Employees
122
Market Cap
172.43M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.43M | 28.04M | 110.47% |
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 74.00M |
| Zentalis Pharmaceuticals | 26.87M |
| Alpha Cognition | 15.26M |
| Keros Therapeutics | 15.01M |
| MediWound | 11.86M |
| Whitehawk Therapeutics | 7.15M |
| Entrada Therapeutics | 3.98M |
| Upstream Bio | 3.16M |
IVVD News
- 2 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Invivyd presents measles antibody candidate VMS063 data at IDWeek 2026 - TheFly
- 15 days ago - Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026 - GlobeNewsWire
- 22 days ago - Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome - GlobeNewsWire
- 5 weeks ago - Invivyd Phase 3 data supports VYD2311 tolerability, says H.C. Wainwright - TheFly
- 5 weeks ago - Invivyd Transcript: Study result - Transcripts
- 5 weeks ago - Invivyd Press release: Study result - Filings
- 5 weeks ago - Invivyd Slides: Study result - Filings